Researches regarding mitogen-inducible gene 6 (Mig-6) have confirmed its role as a tumor suppressor and progesterone resistance factor in endometrium. In this study, after confirming the downregulation of Mig-6 protein in endometrial carcinoma (EC) tissues, the expression of Mig-6 was upregulated in Ishikawa cells by pCMV6-Mig-6 plasmid. We observed the increased apoptosis, decreased proliferation and invasion potential of Ishikawa cells after upregulation of Mig-6. The proapoptosis ability of P4 significantly enhanced by 39.36%, the antiproliferation ability increased by 37.90% and the anti-invasion ability increased by 48.89%, suggesting the antiprogesterone resistance potential of Mig-6 in endometrium. In addition, the results suggested that Mig-6 may induce Ishikawa cell apoptosis through the mitochondrial pathway, inhibit cell proliferation via the extracellular signal-regulated kinase pathway and the anti-invasion potential may associate with matrix metalloproteinase (MMP)-2 and MMP-9 downexpression. Therefore, upregulation of Mig-6 may add a new strategy to suppress endometrial tumorigenesis and attenuate the progesterone resistance during P4 treatment.
INTRODUCTION
Mitogen-inducible gene 6 (Mig-6), also named gene 33, is an immediate early response gene encoding a nonkinase scaffolding adaptor protein. 1 Mig-6 (also known as receptor-associated late transducer (RALT)) acts as a negative feedback regulator of the epidermal growth factor receptor signaling and can be rapidly induced by factors including stresses, hormones and growth factors. 2 Mig-6 localizes in human chromosome 1p36, a locus that has been widely suggested to harbor putative tumor-suppressor genes. 3 Indeed, downregulation or loss of Mig-6 expression has been reported in several human cancers including lung cancer, breast cancer, melanoma and endometrial carcinoma (EC) and is often associated with poor prognosis. [4] [5] [6] [7] [8] [9] It was reported that exogenous overexpression of Mig-6 inhibits apoptosis of human breast cancer cells. 10 Mig-6 is also one of the factors responsible for the progesterone resistance in endometrium. 11 It has been demonstrated that the absence of Mig-6 in mice results in the inability of progesterone (P4) to inhibit 17β-estradiol (E2)-induced uterine weight gain and expression of E2-responsive target genes. 12 We hypothesized that upregulation of Mig-6 may enhance the effect of P4 and have the antitumor effect in endometrium. To address this hypothesis, we transfected EC cell line Ishikawa with pCMV6-ERRFI1 to increase Mig-6 expression and explored the potential of Mig-6 overexpression on apoptosis, proliferation and invasion capability of EC cells. We observed that upregulation of Mig-6 increased apoptosis, decreased proliferation and invasive potential of Ishikawa cells and further enhanced the inhibitory ability of P4 to estrogen-mediated effects.
MATERIALS AND METHODS Sources of tissues EC (stages IA and IB) samples were obtained from 11 women, aged 45-60 years. Control endometria of secretory phase were derived from 10 women with uterine leiomyomas who underwent hysterectomy, aged 40-55 years. All women had not received hormones therapy for at least 3 months before the study and provided informed consent for participation in this study under a protocol approved by the First Affiliated Hospital of Nanjing Medical University.
Western blot
Protein extracts from cells were separated by 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis. The blots that have been transferred to polyvinylidene fluoride membrane (Millipore, Billerica, MA, USA) were blocked with 5% bovine serum albumin) (Sigma-Aldrich, St Louis, MO, USA) in phosphate buffer saline-Tween-20 and processed for immunodetection with primary antibody at 4°C overnight as follows: anti-Mig-6 (1:500, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-phospho-ERK (1:1000, Santa Cruz Biotechnology), anti-ERK (1:1000, Santa Cruz Biotechnology), anticleaved caspase-3 (1:1000, Cell Signaling, Danvers, MA, USA), anti-cyclin D1 (1:1000, Cell Signaling), anti-matrix metalloproteinase-2 (MMP-2) (1:1000, Cell Signaling), anti-MMP-9 (1:1000, Cell Signaling) and anti-glyceraldehyde phosphate dehydrogenase (GAPDH) (1:10 000, Bioworld, Shanghai, China). After incubation with horseradish peroxidase-coupled anti-mouse IgG (1:1000, Bioworld) or anti-rabbit IgG (1:1000, Bioworld) at 37°C for 1 h, bound proteins were visualized using electrochemiluminescence (Millipore) and analyzed using BioImaging Systems (UVP, Upland, CA, USA). The relative band density calculated as a ratio of sample to GAPDH was used as an internal loading control. Experiments were performed three times for each sample.
Transfection, Mig-6 overexpression analysis and steroid treatment EC cell line Ishikawa cell was obtained from Model Animal Research Center, Nanjing University (Nanjing, China), and cultured in Dulbecco's modified Eagle's medium high glucose with 10% fetal bovine serum. Ishikawa cells were respectively transfected with Mig-6 overexpression plasmid (pCMV6-ERRFI1/pCMV-Mig-6, OriGene, Beijing, China) and negative control vector (pCMV6, OriGene) using LipofectamineTM 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacture's guideline when they reached nearly 90% confluence in six-well plates. At 48 h after transfection, Mig-6 protein expression in Ishikawa cells was detected by western blot. For steroid stimulation, Ishikawa cells were starved overnight before ethanol (control), E2 (1 × 10 − 7 M, Sigma-Aldrich) or E2 plus P4 (1 × 10 − 7 M, Sigma-Aldrich) was added into the fresh serum-free Dulbecco's modified Eagle's medium/F12 medium. Each experiment was performed in triplicate.
Cell apoptosis analysis
Multiple hallmarks can be used to identify the cells undergoing apoptosis, such as the presence of cleaved caspase-3 and the staining of exposed phosphatidylserine on cell surface, as demonstrated by the Annexin-V fluorescein isothiocyanate (FITC)/propidium iodide (PI) flow cytometry assay. After plasmid transfection and hormone stimulation, expression of cleaved caspase-3 protein was testified by western blot and cell early apoptosis was determined by assessing the membrane changes using the Annexin-V FITC/PI apoptosis detection Kit (BD Biosciences, Bedford, MA, USA) according to the manufacturer's instructions. Briefly, after 6 h of steroid stimulation, cells were harvested, washed twice with cold phosphate buffer saline and resuspended in 200 μl binding buffer. Then, 5 μl Annexin-V FITC and 5 μl PI were added and incubated for 15 min in the dark at room temperature. Fluorescence from a population of 1 × 10 5 cells was detected using the FACSCalibur flow cytometer (BD Biosciences). The experiments were performed in duplicate and repeated three times.
Cell proliferation assay
At 48 h after transfection of pCMV6 and pCMV6-Mig-6, Ishikawa cells were passaged and stimulated with E2 (1 × 10 − 7 M) or E2 plus P4 (1 × 10 − 7 M) for 6 h. Bromodeoxyuridine (BrdU)/PI cell proliferation assay was conducted according to the manufacturer's recommendations (Roche Molecular Biochemical, Indianapolis, IN, USA). Briefly, Ishikawa cells were incubated with BrdU labeling reagent for 2 h and fixed with 75% ethanol at 4°C overnight. On the following day, the cells were resuspended in 2 N HCL/ 0.5% Tx-100 and then 0.1 M NaB4O7 (pH 8.5), both for 30 min at room temperature. After centrifugation, cells were successively incubated with anti-BrdU mouse monoclonal antibody, FITC-conjugated rabbit anti-mouse IgG and PI solution according to the order. The colored products were tested using FACSCalibur flow cytometer. Cyclin D1 and phosphorylated form of extracellular signal-regulated kinase (p-ERK) expression have also been observed with western blot after Mig-6 overexpression and steroid treatment. All assays were conducted in duplicate and the experiment was performed at least three times.
Matrigel invasion assay
Cellular invasion was determined using a modified Matrigel Transwell chamber (Millipore) assay according to the manufacturer's instructions. At 48 h after plasmid transfection and hormone stimulation, Ishikawa cells (3 × 10 4 cells) resuspended in 100 μl serum-free medium were seeded into the upper inserts coated with 100 μl Matrigel (1:8 diluted, BD Biosciences). Then, 600 μl complete medium with 10% fetal bovine serum was added into the lower chamber. After incubation for 24 h, the noninvaded cells on the upper membrane surface were wiped off with a cotton swab. The cells migrating across the membrane were fixed, stained and counted manually in 5 random microscopic fields (×200). Results are reported as invasive cell index, that is, the transmembrane cells in conditioned group divided by that in only ethanol-treated group. All experiments were performed independently in triplicate.
Statistical analysis SPSS 20 .0 (SPSS, Chicago, IL, USA) was used for statistical analysis. Data were presented as mean ± s.d., and checked by the normality assumption and the homogeneity of variances assumption in one-way analysis of variance. P o0.05 was considered as statistically significant.
RESULTS

Downregulation of Mig-6 in human endometrial cancer
Histopathologically confirmed endometrioid adenocarcinoma samples (n = 11) and normal endometria in secretory phase (n = 10) were obtained for tissue protein extraction respectively and Mig-6 level testing by western blot. All EC cases enrolled in our study were in IA or IB phase according to the International Federation of Gynecology and Obstetrics (FIGO) staging system (2009). Nine patients presented with grade 1 differentiation and two patients with mostly grade 1 and focal grade 2. As shown in Figure 1a and b, Mig-6 protein expression in EC tissue decreased by 48.11% compared with control endometrium (P o 0.05).
Mig-6 overexpression in Ishikawa cells
At 48 h after transfection of pCMV6 and pCMV6-Mig-6 plasmid, the expression of Mig-6 protein in Ishikawa cells was assessed via western blot. As shown in Figure 2 , the level of Mig-6 protein in cells transfected with pCMV6-Mig-6 was significantly higher than that in negative control (NC) group (P o 0.05). Figure 3a and b, without hormone stimulation, the early apoptosis rate of Ishikawa cell in Mig-6 overexpression group was 2.67 times of that in NC group (7.2 ± 1.3% vs 2.7 ± 0.93%, P o0.05). In the NC group, early apoptosis rate induced by E2 plus P4 was 3.06 times higher than that of E2 stimulated alone (9.5 ± 0.53% vs 3.1 ± 0.31%, P o 0.01), and upregulation of Mig-6 further enhanced the proapoptotic effect of P4 to 1.39 times (13.1 ± 2.62% vs 9.5 ± 0.53%, P o 0.05). A series of proteins were involved in the process of cell apoptosis, such as caspases (cysteine aspartyl-specific proteases), B-cell lymphoma-2 (Bcl-2) family proteins, P53 and survivin. Caspase-3 is the 'executioner' or 'effector caspases' of apoptosis, when cleaved and activated by initiator caspases, it triggers death of the cell. 13 As shown in Figure 3c , the expression of cleaved caspase-3 protein was elevated upon over-expression of Mig-6 without steroid stimulation (P o 0.05), however, cleaved caspase-3 expression did not further increase when treated with E2 plus P4. In addition, the expression of Bcl-2 protein was significantly decreased with no remarkable change of Bax, thus Bax/Bcl-2 ratio was elevated upon over-expression of Mig6.
Mig-6 overexpression increased apoptosis of Ishikawa cells As shown in
Mig-6 overexpression inhibited proliferation of Ishikawa cells
To investigate the effect of Mig-6 overexpression on proliferation of Ishikawa cells, we performed BrdU incorporation assay. As shown in Figure 4a and b, Mig-6 overexpression led to significantly decreased amount of cells in the S phase, the BrdU incorporation rate of cells in Mig-6 overexpression group was 70.28% of that in NC group (30.5 ± 4.3% vs 43.4 ± 2.4%, Po 0.05), and E2 treatment could not increase cell proliferation as that in NC group. In addition, upregulation of Mig-6 enhanced the antiproliferation effect of P4 by 37.90% (15.4 ± 2.0% vs 24.8 ± 1.4%, Po 0.05).
Cyclin D1 is a cell cycle-regulatory protein associated with cell proliferative activity that could switch the cell cycle from G1 phase to S phase and promote DNA synthesis. 14 The expression of cyclin D1 and phosphorylation of ERK was measured by western blot. As shown in Figure 4c and d, Mig-6 overexpression induced a significant decrease in cyclin D1 level coincident with reduced ERK phosphorylation.
Upregulation of Mig-6 attenuated invasive capability of Ishikawa cells
To explore whether Mig-6 overexpression has any influence on invasive potential of Ishikawa cells, Matrigel invasion assays were conducted. As shown in Figure 5a and b, the amount of cells transmembrane in Mig-6 overexpression group was 72.38% of that in NC group; when treated with E2, the invasive cell index of Mig-6 overexpression group decreased by 32.37% (0.94 ± 0.25 vs 1.39 ± 0.27, P o 0.05), whereas with P4 treatment, the invasive cell index of Mig-6 overexpression group decreased by 48.89% (0.23 ± 0.08 vs 0.45 ± 0.09, P o0.05).
MMPs, a family of Zn-dependent endopeptidases, degrade all kinds of extracellular matrix proteins, which is an important factor participating in cancer cell invasion. [15] [16] [17] Therefore, MMP-2 and -9 protein expressions were detected by western blot. Our results showed that Mig-6 overexpression significantly decreased both MMP-2 and -9 protein level in Ishikawa cells (Figure 5c ).
DISCUSSION
Endometrioid-type (type I) endometrial adenocarcinoma and its precursor lesion, endometrial hyperplasia, are associated with unopposed estrogen exposure. 18 An imbalance caused by increased estrogen action and/or decreased P4 action can result in abnormal endometrial proliferation and EC. 19 Jeong et al. 12 observed that Mig-6 expression was significantly decreased in patients with EC compared with endometrial biopsies taken from normal women during the secretory phase of the cycle using real-time quantitative polymerase chain reaction (qPCR) and immunohistochemistry. Here, we confirmed the downregulation of Mig-6 in EC with western blot.
In Mig-6-null mouse, it is clear that lack of Mig-6 causes hyperproliferation of the cells in the skin and gallbladder with spontaneous tumor formation. 3, 20 Fueger and colleagues 21 reported that adenoviral-mediated overexpression of Mig-6 exacerbated cell apoptosis through caspase-3-mediated pathways in pancreatic cells. In this study, we chose pCMV6-ERRFI1 to increase Mig-6 expression in Ishikawa cells and observed that upregulation of Mig-6 effectively increased the early apoptosis rate of cells; meanwhile, cleaved caspase-3 protein level was also elevated. Our findings that Mig-6 promoted apoptosis are in concordance with previous reports in endometrial cancer and non-small-cell lung cancer cell lines. 9, 22 Apoptosis is mainly regulated by intrinsic and extrinsic pathways. The intrinsic cell death pathway is regulated by Bcl-2 family proteins that have either antiapoptotic or proapoptotic functions. The antiapoptotic Bcl-2 proteins inhibit apoptosis by inhibiting proapoptotic proteins such as Bax, whose oligomerization would lead to mitochondrial membrane permeabilization and release of second mitochondria-derived activator of caspase (SMAC, also called DIABLO) and cytochrome c, and then 'apoptosome' formed and caspases were activated, eventually leading to cell suicide. 13 Our results showed the Bax/Bcl-2 ratio was elevated in Mig-6 overexpression group, suggesting Mig-6 may induce Ishikawa cell apoptosis through the mitochondrial pathway.
The p-ERK protein, as a downstream factor of Mig-6, is involved in the regulation of cell proliferation, apoptosis and the induction of drug resistance. 23, 24 Previous study showed that Mig-6 knockdown led to a significant increase in p-ERK. 25, 26 Mig-6 overexpression promotes apoptosis through inhibition of the ERK pathways in non-small-cell lung cells. 9 In addition, as a negative feedback regulator of the epidermal growth factor receptor signaling, Mig-6 binds to the tyrosine kinase domains of epidermal growth factor receptor and inhibits the tyrosine kinase activity. 27 RAS/RAF/ERK pathway is a downstream signal pathway of epidermal growth factor receptor that is associated with cell proliferation. Fiorini et al. 28 demonstrated that activation of the RAS/RAF/ERK pathway was necessary and sufficient to drive Mig-6 expression. In our study, we observed that Mig-6 overexpression decreased 29.72% of Ishikawa cell proliferation and induced a significant decrease in cyclin D1 level coincident with reduced ERK phosphorylation. These results suggested that the antiproliferation effect of Mig-6 on Ishikawa cells may involve the feedback inhibition of RAS/RAF/ERK pathway.
Local invasion is a principal characteristic of advanced endometrial cancer that involves detachment, proteolysis, penetration and so on. 29 High levels of MMPs that are usually present at malignant cancer cells degrade extracellular matrix and ultimately invade other tissues. 30 Especially, MMP-2 and -9 are the two major enzymes to degrade type IV collagen, a main component of the basement membrane. 31 Our results showed that overexpression of Mig-6 inhibited cell invasive potential and expression of the invasion-relevant MMP-2 and -9. Therefore, we deduced that Mig-6 may attenuate the invasive capability of Ishikawa cells by downregulating MMP-2 and -9 expression.
EC is a disease of perimenopausal women. However, ∼ 3-14% of endometrial cancer cases are diagnosed in women ≥ 40 years of age who want to preserve their fertility. 32, 33 Young women with endometrial carcinoma are usually estrogen dependent and identified at an early stage: well differentiated with minimal or no myometrial invasion. 34 Although surgical procedures are still the first line and most effective treatments for the early stage of EC, progestin therapy is also effective for atypical endometrial hyperplasia and early EC in many young women who desire to maintain their fertility. 35 Initial response rates with progestin therapy are 83 to 94% for complex atypical hyperplasia, and 57 to 75% for early-stage, well-differentiated endometrial cancer. 34 Fertility-sparing progestin therapy has been recommended for patients with presumed early-stage, welldifferentiated, endometrioid-type endometrial adenocarcinoma with no evidence of myometrial invasion or extrauterine spread. 36 However, 430% of women with estrogen-dependent, welldifferentiated type I EC fail to respond to progesterone treatment because of progesterone resistance, 37 and the underlying mechanisms behind this are still poorly understood. Attenuated responsiveness, or resistance, to progesterone has also been implicated in the pathophysiology of endometriosis and polycystic ovary syndrome. [38] [39] [40] Approximately 30% of women with polycystic ovary syndrome fail to respond to P4-based oral contraceptive therapy and progress to the development of atypical hyperplasia and further transformation to EC. 41 As P4 inhibits tumor cell growth and induces differentiation regulated by the progesterone receptor (PR), the lack of PR expression leads to a lack of P4 protection against the growthpromoting effects of estrogen, and downexpression of PR is the main cause of progesterone resistance. 42 Kim et al. 12, 43 identified Mig-6 as a target of PR action using a genome-wide gene expression profiling. P4 treatment had no effect in hyperplasic phenotype mice where Mig-6 was deleted in both the epithelial and stromal compartments of the uterus. 22 In our study, over-expression of Mig-6 significantly enhanced pro-apoptosis, anti-proliferation and anti-invasion function of P4, suggesting that Mig-6 may be involved in the pathway of P4 effect on attenuating progesterone resistance in endometrium. Nevertheless, we need Mig-6 suppressed tumor and progesterone resistance further study to assess how Mig-6 participates in the P4 effect pathway.
In conclusion, we have identified the important role that Mig-6 played in the control of apoptosis, proliferation and invasion capability of EC cells. Meanwhile, the present study provides evidence that Mig-6 overexpression enhances the ability of P4 to antagonize E2-mediated effect. Therefore, upregulation of Mig-6 may add a new strategy to suppress endometrial tumorigenesis and attenuate the progesterone resistance during P4 treatment.
